Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer drug trial halted early: what happened?

NCT ID NCT04189614

Terminated Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called cofetuzumab pelidotin for people with a specific type of advanced lung cancer (non-small cell lung cancer) that had returned after other treatments. The drug was designed to target a protein called PTK7 found on cancer cells. The study was stopped early, and results are limited. It involved 65 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

  • Asan Medical Center /ID# 222280

    Seoul, Seoul Teugbyeolsi, 05505, South Korea

  • CHA Bundang Medical Center /ID# 232514

    Seongnam, Gyeonggido, 13496, South Korea

  • Duplicate_Stanford University School of Med /ID# 213450

    Stanford, California, 94305-2200, United States

  • Highlands Oncology Group, PA /ID# 215383

    Springdale, Arkansas, 72762, United States

  • Hospital Universitario Fundacion Jimenez Diaz /ID# 215110

    Madrid, 28040, Spain

  • Hospital Universitario HM Sanchinarro /ID# 215102

    Madrid, 28050, Spain

  • Hospital Universitario Vall de Hebron /ID# 215729

    Barcelona, 08035, Spain

  • Linkou Chang Gung Memorial Hospital /ID# 222603

    Taoyuan City, 333, Taiwan

  • Moffitt Cancer Center /ID# 215101

    Tampa, Florida, 33612-9416, United States

  • National Cancer Center Hospital /ID# 218536

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East /ID# 218537

    Kashiwa-shi, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital /ID# 222602

    Tainan, 704, Taiwan

  • Oncology Consultants /ID# 215932

    Houston, Texas, 77030-3306, United States

  • Rabin Medical Center. /ID# 217537

    Petah Tikva, Central District, 4941492, Israel

  • Rambam Health Care Campus /ID# 217536

    Haifa, 3109601, Israel

  • Samsung Medical Center /ID# 222906

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Sylvester Comprehensive Cancer Center /ID# 216433

    Miami, Florida, 33136-1002, United States

  • Tennessee Oncology, PLLC /ID# 215326

    Nashville, Tennessee, 37203, United States

  • The Chaim Sheba Medical Center /ID# 217538

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The Ohio State University /ID# 211088

    Columbus, Ohio, 43210, United States

  • Univ of Colorado Cancer Center /ID# 215295

    Aurora, Colorado, 80045, United States

  • University of Alabama at Birmingham - Main /ID# 213605

    Birmingham, Alabama, 35233, United States

  • University of Texas MD Anderson Cancer Center /ID# 215876

    Houston, Texas, 77030, United States

  • Virginia Cancer Specialists - Fairfax /ID# 216427

    Fairfax, Virginia, 22031, United States

  • Washington University-School of Medicine /ID# 213453

    St Louis, Missouri, 63110, United States

  • Yonsei University Health System Severance Hospital /ID# 222281

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.